Members may also exclude from patentability: plants and animals other than micro-organisms, and essentially biological processes for the production of plants or animals other than non-biological and microbiological processes. However, Members shall provide for the protection of plant varieties either by patents or by an effective sui generis system or by any combination thereof. The provisions of this subparagraph shall be reviewed four years after the date of entry into force of the WTO Agreement.
Introduction: terminology, definition and scope
Article 27.3(b) addresses one of the most controversial issues covered by TRIPS. The often called "biotechnology clause" describes subject matter that Members may exclude from patentability while, at the same time, specifically obliges Members to protect microorganisms and certain biotechnological processes.
The drafting of this clause -the single one in the whole TRIPS Agreement subject to an early review 643 -reflected, on the one hand, the strong interests of some developed countries in ensuring protection of biotechnological innovations and, on the other, the important differences existing among such countries with regard to the scope of protection, as well as the concerns of many developing countries about the patentability of life forms.
Since the adoption of the Agreement, the differences in the treatment of biotechnological inventions among developed countries have been reduced, 644 but not eliminated. 645 Many developing countries have indicated, in the process of review of Article 27.3(b) and in preparations for the Third WTO Ministerial Conference (December 1999), their discomfort with the implications of this provision, particularly in view of several cases of protection, in developed countries, of biological 643 Which should have taken place in 1999. 644 Particularly with the approval of the EU Directive on Biotechnological Inventions (No. 96/9/EC of March 11, 1996) . 645 Thus, plant varieties and animal races are not patentable in Europe, while they are eligible for protection in the USA.
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resources or traditional knowledge (such as quinoa, ayahuasca and curative uses of turmeric) 646 originating in developing countries. In the opinion of these countries, there is need to reconcile Article 27.3(b) with the relevant provisions of the Convention on Biological Diversity, particularly on prior informed consent and benefit sharing.
Article 27.3(b) leaves considerable flexibility for Members to adopt different approaches to the patentability of inventions relating to plants and animals, but unambiguously requires the protection of micro-organisms. 647 In addition, this Article obliges Members to provide protection for "plant varieties". The distinction between a "plant", that is, a living organism that belongs to the plant kingdom, and a "plant variety" 648 must be borne in mind for the interpretation of this clause. For example, when a pest-resistant gene is introduced by means of genetic engineering in a certain number of cotton plants 649 , one or more "transgenic" plants are obtained. The patentability of these plants may or may not be admitted under national law. These plants, however, do not necessarily constitute a "plant variety", unless whenever cultivated, the resulting plants retain certain predetermined characteristics and can be propagated unchanged.
In case a Member chooses to protect living organisms through patents, . 648 According to the UPOV Convention (as revised in 1991) a "plant variety" is "a plant grouping within a single botanical taxon of the lowest rank, which grouping, irrespective of whether the conditions for the grant of a breeder's right are fully met, can be defined by the expression of the characteristics resulting from a given genotype or combination of genotypes, distinguished from any other plant grouping by the expression of at least one of the said characteristics and considered as a unit with regard to its suitability for being propagated unchanged". One essential element in this definition is that a plant "variety" is a grouping of plants which retain their distinguishing characters when reproduced from seeds or by asexual means (for example, cuttings). See National Research Council, Committee on Managing Global Genetic Resources: Agricultural Imperatives, Managing Global Genetic Resources. Agricultural Crop Issues and Policies, National Academy Press, Washington, D.C. 1993, p. 412. Expressed in less technical terms, a plant variety is the technical modification of a naturally existing plant. The result of this modification is a transformed plant which retains certain characteristics when reproduced from seeds or by asexual means (the latter meaning reproduction not from seeds but through methods such as cutting, division, layering, etc.). 649 While inserting genes is the task of biotechnologists, developing a variety is the responsibility of breeders. "Plant breeding" is the science-based activity that aims to improve the quality and yield of plant varieties yield, see W. While Article 27.3(b) is flexible about the form of protection of plant varieties, it forced the introduction of IPR protection in an area in which most developing countries had none before the adoption of the Agreement. This obligation has raised concerns in some of those countries about the impact of IPR protection on farming practices (particularly the re-use and exchange of seed by farmers), genetic diversity, and food security.
History of the provision

Situation pre-TRIPS
After the decision by the U.S. Supreme Court in Diamond v. Chakrabarty (1980), 652 which accepted for the first time a patent on a living organism per se, 653 the patentability of such matter expanded in industrialized countries to include cells and sub-cellular parts, including genes, as well as multicellular organisms. An accepted principle since the 1980s in those countries was that the fact that an invention consisted of, was based on or employed living matter, was not a sufficient reason to exclude patent protection, including for biological materials pre-existing in nature (provided that the latter were claimed in an isolated or purified form). Despite this trend, considerable differences remain in those countries with regard to the scope of patentability of biotechnology-related inventions. Divergences were even more profound with respect to developing countries.
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In the field of plant varieties, few countries (most of them developed countries) had adopted at the time of the negotiation of TRIPS specific regulations on breeders' rights and had adhered to the Convention for the Protection of New Varieties of Plants ("the UPOV Convention") of December 2, 1961, which was subsequently revised in 1972, 1978 and 1991. 655 In addition, the 1978 Act of the UPOV Convention did not permit the provision of both breeders' rights and patent protection for the same genera or species (Article 2).
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generis systems that do not rely on the same criteria for protection as patents (i.e. novelty, inventive step and industrial applicability). For details, see Sections 3 and 5 of this chapter. 651 For more details, see Section 3 of this chapter. 652 447 U.S. 303 (1980) . 653 The patent, filed in 1972, related to a genetically modified microorganism. It asserted 36 claims related to the invention of "a bacterium from the genus Pseudomonas containing therein at least two stable energy-generating plasmids, each of these plasmids providing a separate hydrocarbon degradative pathway". 654 sentence of the same Article that introduces an exception for one particular classification (plant varieties), the scope of the exception under Article 27.3(b) is to be interpreted in broad terms. Consequently, Members may exclude plants as such (including transgenic plants), 658 plant varieties (including hybrids), as well as plant cells, seeds and other plant materials. They may also exclude animals (including transgenic) and animal races.
Members may opt to exclude from patentability only certain categories of plant and animal inventions. Thus, in European countries the prohibition to patent a plant "variety" does not prevent the patenting of plants as such. Similarly, the granting of a patent by the European Patent Office on the "Harvard oncomouse" (a mouse genetically modified to facilitate the testing of anti-cancer drugs) was also based on the judgment that it was not a "race" but a specifically altered "animal". A "micro-organism" is an organism that is not normally perceptible by the eye. The scientific concept of "micro-organism" refers to "a Member of one of the following classes: bacteria, fungi, algae, protozoa or viruses." 660 An important question is whether microorganisms as found in nature should be patented under this provision. It is generally accepted that "to be patentable, a micro-organism cannot be as it exists in nature". 661 However, in some jurisdictions it is sufficient to isolate a microorganism and identify a use therefore to obtain a patent.
Thus, in countries that are parties to the European Patent Convention a patent may be granted when a substance found in nature can be characterized by its structure, by its process of isolation or by other criteria, if it is new in the sense that it was not previously available to the public. The European Directive on Biotechnological Inventions clarifies that "biological material which is isolated from its natural environment or processed by means of a technical process may be the subject of an invention even if it already occurred in nature" (Article 3.2).
In the United States, an isolated or purified form of a natural product is patentable. The concept of "new" under the novelty requirement does not mean "not preexisting" but "novel" in a prior art sense, so that the unknown but natural 658 Note that the transgenic character alone is not sufficient for the plant to be considered a plant variety. On top of the transgenic modification, the transformed plant would have to be stable in its characteristics, i.e. retain them after reproduction. See above, under Section 1. 659 existence of a product does not preclude the product from the category of statutory subject matter. Similarly, in Japan the Enforcement Standards for Substance Patents stipulated that patents can be granted on chemical substances artificially isolated from natural materials, when the presence of the substance could not be detected without prior isolation with the aid of physical or chemical methods.
Members may also opt for a narrower scope of patentability, confining it to microorganisms that have been genetically modified. 662 TRIPS, in effect, does not define what an "invention" is; it only specifies the requirements that an invention should meet in order to be patentable (Article 27.1).
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Another important practical issue relates to the patenting of cells, genes and other sub-cellular components. In many jurisdictions, the patenting of these materials has become common practice. 664 Though these materials are not visible to the naked eye, they do not constitute "microorganisms" and, therefore, are not subject to the obligation established in Article 27.3 (b).
Processes
Members may also exclude from patentability . . . essentially biological processes for the production of plants or animals other than non-biological and microbiological processes.
Another possible exclusion from patentability relates to essentially biological processes for the production of plants or animals. Processes for the therapeutic treatment or utilization of plants and animals are not covered by the exception. 665 The notion of "essentially biological process" has been defined by the European Patent Office on the basis of the degree of "technical intervention"; if the latter plays an important role in the determination of or control over the results, the process may be patentable. 666 Under this notion, conventional breeding methods are generally not patentable. In contrast, methods based on modern biotechnology (e.g., tissue culture, 667 insertion of genes in a plant) where the technical intervention is significant, would be patentable. 662 See, e.g., Article 10.XI of the Brazilian Industrial Property Code (Law No. 9.279, 14 May 1996), which excludes from patentability "biological materials found in nature", even if isolated, including the "genome or germplasm" of any living being. 663 See Chapter 17. 664 For instance, genetic materials may be patented in many countries if claimed in a non-naturally occurring form, that is, as an isolated or purified molecule. In the United States, the doctrine of Re Deuel (1995) has paved the way for the patenting of DNA even when encoding known proteins, on the grounds that -due to the degeneracy of the genetic code -their structure could not have been predicted. In Europe, however, gene sequences which code for a known protein are generally now regarded as prima facie obvious, although such was not the case in the earliest days of molecular biology. 665 Diagnostic, therapeutic and surgical methods for the treatment of animals may be exempted from patentability under Article 27.3 (a) of the TRIPS Agreement. 666 Guidelines for Examination of the EPO, No. X-232.2.
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Patents: biotechnological inventions
The exclusion of "essentially biological processes" does not extend to "nonbiological" processes for the production of plants or animals. It does not extend either to microbiological processes which are generally patentable. It is not so simple to determine when a process is "microbiological". In principle, this concept would include any process that uses or modifies microorganisms. There are, however, processes that only include one or more steps that are "microbiological." In accordance with the European Directive on Biotechnological Inventions, such processes should be deemed as "microbiological" if at least one essential step is microbiological (Article 2.2).
Plant varieties
However, Members shall provide for the protection of plant varieties either by patents or by an effective sui generis system or by any combination thereof.
TRIPS obliges Members to protect plant varieties by means of patents, an effective sui generis regime or a combination of both. While the granting of patents is regulated under considerably detailed standards, the only requirement with respect to a sui generis system is that it must confer an "effective" protection. Countries can, thus, determine the scope and contents of the rights to be granted.
The flexibility permitted by Article 27.3(b) in relation to the form of protection for plant varieties has been the reflection, to a large extent, of the lack of consensus on the matter among the industrialized countries during the TRIPS negotiations. While in the USA, Australia and Japan a plant variety may be patented as such, this is not the case in Europe, as mentioned above. The reference to a "sui generis system" may be deemed to suggest the breeder's rights regime, as established in the UPOV Convention. However, the possibility is open to combine the patent system with the breeders' rights regime, or to develop other "sui-generis" forms of protection.
Industrial property protection for plant varieties is not new. In the 1920s and 1930s several countries introduced legislation that gradually evolved into a sui generis system of protection ("breeders' rights") distinct from the patent system. Based on requirements of distinctness, novelty, uniformity and stability, breeders' rights have typically been permitted to control the commercialization of propagating materials (like seeds), without interfering, however, either with the use of saved seeds by farmers on their own land ("farmers' privilege") or with the development of new varieties by a third party taking as a starting point a protected variety ("breeders' exemption"). Such sui generis regime obtained recognition at the international level in the 1960s with the adoption of the UPOV Convention. The Convention introduced minimum standards for the recognition of breeders' rights and, as mentioned, it initially prohibited the provision of patent and sui generis protection for plant varieties.
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668 The limitation contained in Article 2 of the 1978 Act was not applicable to countries that provided double protection before the expiry of the period for signature of the 1978 Act (Article 37). This allowed the United States to maintain both patents and breeders' rights for plant varieties.
Breeders' rights protect plant varieties, which are new, distinct, uniform and stable. They grant the faculty to exclude non-authorized persons from using and multiplying propagating materials of protected varieties. Several features differentiate breeders' rights from patents. The former apply to a specific variety (which must physically exist), while patents may refer to genes, cells, plants, seeds or (where allowed) the varieties as such. Another important difference is that the breeder's rights system generally allows farmers to re-use in their own exploitations the seeds they have obtained, a possibility that patents generally exclude.
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In addition, under breeders' rights protected varieties may be used for further breeding without the authorization of the title-holder ("breeders' exemption"). This may not be possible, depending on national legislation, under patent law.
Review
The provisions of this subparagraph shall be reviewed four years after the date of entry into force of the WTO Agreement. The Council has addressed these items together, due to their interrelated character. Despite consultations held by the Chair, Members have so far not been able to remove their substantive differences over these issues. A number of proposals made under the three items above will be analyzed in the following paragraphs. "The African Group maintains its reservations about patenting any life forms as explained on previous occasions by the Group and several other delegations. In this regard, the Group proposes that Article 27.3(b) be revised to prohibit patents on plants, animals, micro-organisms, essentially biological processes for the production of plants or animals, and non-biological and microbiological processes for the production of plants or animals. For plant varieties to be protected under the TRIPS Agreement, the protection must clearly, and not just implicitly or by way of exception, strike a good balance with the interests of the community as a whole and protect farmers' rights and traditional knowledge, and ensure the preservation of biological diversity.
In any case, the Council for TRIPS must ensure that the exceptions for ordre public or morality in paragraph 2 of Article 27 are not rendered meaningless by any provisions in its paragraph 3(b) through requiring Members to do what is otherwise contrary to ordre public and morality in their societies. The barest minimum in this regard, would be to clarify that paragraph 3(b) does not in any manner restrict the rights of Members to resort to the exceptions in paragraph 2.
[. . . ]
As pointed out above, the African Group has consistently raised serious concerns about patents on life forms and research tools and on the basis of these concerns the Group has maintained that there should not be a possibility, within the framework of the TRIPS Agreement, of patents on micro-organisms as well as on nonbiological and microbiological processes for the production of plants and animals.
It is the view of the Group that the distinction drawn in Article 27.3(b) for micro-organisms, and for non-biological and microbiological processes for the 673 See, e. in the above sense, referring, inter alia, to their biotechnology industries. 675 The EC, for example, has proposed that those Members seeking to avoid the patenting of natural materials could make use of the TRIPS flexibilities, i.e. to define narrowly the patentability criteria. In this vein, genetic resources occurring in nature would not be patentable (failing to meet the novelty requirement). 676 The aim of some developed countries, if a revision did take place, would be to eliminate the exception for plants and animals, and to establish that the UPOV Convention as revised in 1991 should be the only means of protection available for plant varieties, excluding other sui generis systems. Thus, according to the United States, the TRIPS Council should consider "whether it is desirable to modify the TRIPS Agreement by eliminating the exclusion from patentability of plants and animals and incorporating key provisions of the UPOV agreement regarding plant variety protection." 677 For many developing countries, in contrast, it would be important to maintain the exception for plants and animals, as well as the flexibility to develop sui generis regimes on plant varieties which are suited to the seed supply systems of the countries concerned. The main concern of many developing countries is that TRIPS does not require patent applicants whose inventions incorporate or use genetic material or associated knowledge to comply with certain obligations under the Convention for Biological Diversity (CBD). This convention makes access to genetic material subject to prior informed consent of and equitable benefit sharing with the Contracting Party providing the genetic resources. 680 Developing countries have repeatedly voiced concern about possible misappropriation of their genetic resources by developed country patent applicants. 681 In order to address such concerns, developing countries have proposed in the Council for TRIPS to amend TRIPS in a way as to require an applicant for a patent relating to biological materials or traditional knowledge to provide, as a condition for obtaining the patent: 
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Overall, the issue remains controversial.
3.5.3
The protection of traditional knowledge (TK) and folklore Discussions in the Council for TRIPS have mainly focused on the question of the right forum for TK protection. Developing countries are almost unanimous in their firm support of the idea that TK protection should be negotiated in the WTO. 685 In these countries' view, any other forum, including WIPO, would not provide the appropriate means for the enforcement of rights.
On the other side, developed Members are opposed to treating TK in the WTO and insist that the matter be dealt with under WIPO auspices (in the IGC).
686 Some of the arguments relate to the expertise of WIPO as well as to the overloaded Doha agenda of the WTO that would not permit sufficient resources to take up a new issue such as TK.
Another controversial issue in this context is the term of protection of TK. While developing countries support the African Group's position 687 that there should be no limitation, like in the case of GIs, developed Members stress the necessity to preserve the public domain in this area. 
WTO jurisprudence
There is no WTO jurisprudence so far on this subject. 686 See, e.g., EC October 2002, p. 2: "The EC support further work towards the development of an international sui generis model for legal protection of TK in WIPO. At this stage, the TRIPS Council is not the right place to negotiate a protection regime for a complex new subject matter like TK or folklore. This is an issue where the WTO should ideally be able to build on the work done by the WIPO Intergovernmental Committee on Intellectual Property, Genetic Resources, Traditional Knowledge and Folklore. Depending on the outcome of the WIPO process, the TRIPS Council will have to determine whether this result warrants further work in the WTO. 688 This point was raised by the EC at the March 2004 Meeting of the Council for TRIPS. The EC maintained that TK and GIs are different, the latter protecting only the name, while TK protects the knowledge incorporated in a product. 689 The USA requested consultations under the DSU against Argentina in relation, inter alia, to the patentability of micro-organisms (WT/DS 196/1). In order to be eligible for protection, a plant variety must meet the following requirements:
Other international instruments
UPOV
(i) Novelty. The variety must not -or, where the law of a state so provides, must not for more than one year -have been offered for sale or marketed with the consent of the breeder in the state where the applicant seeks protection, nor for more than four years (six years in the case of grapevines and trees, including rootstocks) in any other state. The 1991 Act makes the one-year period of grace compulsory and requires that "propagating or harvested material of the variety" must not have been "sold or otherwise disposed of to others" (Article 6 of the 1991 Act).
(ii) Distinctness. The variety must be clearly distinguishable by one or more important characteristics from any other variety whose existence is a matter of common knowledge (Article 7 of the 1991 Act).
(iii) Uniformity. Subject to the variation that may be expected from the particular features of its mode of propagation, the variety must be sufficiently uniform in its relevant characteristics (Article 8 of the 1991 Act).
(iv) Stability. Subject to the variation that may be expected from the particular features of its mode of propagation, the variety must be stable in its essential characteristics. This is the case if the latter remain unchanged after repeated propagation or, in the case of a particular cycle of propagation, at the end of each such cycle (Article 9 of the 1991 Act).
(v) Denomination. The variety must be given a denomination enabling it to be identified; the denomination must not be liable to mislead or to cause confusion as to the characteristics, value or identity of the new variety or the identity of the breeder (Article 5 (2) in conjunction with Article 20 (2) of the 1991 Act).
The Convention in Article 11 provides for the so-called right of priority. Any breeder (national or a resident of a Member state) may file a first application for 690 Though new members to UPOV can only join the 1991 Act, many countries still remain obliged under the 1978 Act of the Convention. 691 The main changes included the expansion of the coverage of protection to all plant genera and species; the extension of the breeder's exclusive rights, in certain cases, beyond reproductive material, to harvested material and products obtained through illegal use of propagating material; allowing members the option to accumulate breeders' rights and patent protection for plant varieties (a possibility excluded under the 1978 Act); and introduction of the concept of "essentially derived varieties" (For an explanation of this term, see below under this Section).
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protection of a given plant variety in any of the Member states. If the breeder files an application for the same variety in any other Member state within 12 months from the filing of the first application, the breeder will enjoy a right of priority for this later application. Protection is granted after the competent authority of the Member state in which protection is sought has ascertained that the plant variety for which protection is sought fulfils the above criteria. The examination of homogeneity and stability, as mentioned, must take into account the particularities of the mode of propagation of the variety.
According to Article 14(1)(a) of the Convention, as amended in 1991, there are seven acts of exploitation for which the breeder's authorization is required: (i) production or reproduction (multiplication); (ii) conditioning for the purpose of propagation; (iii) offering for sale; (iv) selling or other marketing; (v) exporting; (vi) importing; (vii) stocking for any of these purposes.
The above mentioned rights may be exercised in respect of the propagating material, and also in respect of the harvested material (including whole plants and parts of plants), provided that the latter has been obtained through the unauthorized use of propagating material, and that the breeder has had no reasonable opportunity to exercise his right in relation to the propagating material.
The breeder's right extends, in addition to the protected variety itself, to varieties which are not clearly distinguishable from the protected variety, which are "essentially derived" from the protected variety, 692 and those whose production requires the repeated use of the protected variety.
As in the case of UPOV 1978, according to UPOV 1991 the underlying genetic resource embodied in a protected plant variety is freely available to third parties for the purpose of breeding other varieties (breeders' exemption). This is crucial for the further improvement of existing varieties. However, Article 15(1)(iii) in conjunction with Article 14(5) of UPOV 1991 now makes clear that the breeders' exemption does not apply where the third party's breeding activities do not result in a genuinely new variety, but in one that is essentially derived from the initial, protected variety.
693 This is because the breeder's exclusive rights to the initial variety extend to those essentially derived varieties, as observed above. 694 692 See Article 14 (5)(a) of UPOV 1991. A variety which is essentially derived from a protected variety and which fulfils the criteria of novelty, distinctness, uniformity and stability, may be the subject of protection by a third party but cannot be exploited without the authorization of the breeder of the original variety. The concept of essential derivation applies to varieties which are predominantly derived from another variety and which, except for the differences that result from the act of derivation, conform to the initial variety in the expression of the essential characteristics that result from the genotype or a combination of genotypes of the initial variety (Article 14(5) of the UPOV Convention, 1991 Act). 693 694 In effect, this provision means that the breeder of breeders' right-protected variety A has the right to demand that the breeder of variety B secure his or her authorization to commercialise B if it was essentially derived from A. The main idea here is that breeders should not be able to acquire protection too easily for minor modifications of extant varieties or free-ride without doing any breeding of their own, problems that the increased application of biotechnology in this field appeared likely to exacerbate. Beyond resolving these particular issues, the provision was It can thus be noted that the new concept of "essentially derived" varieties as introduced by UPOV 1991 enlarges the exclusive right of breeders, extending those rights from the initial variety to all varieties essentially derived therefrom (Article 14 (5)(a)(i)).
Under UPOV 1978, farmers were permitted to save seeds for re-use in their exploitations. UPOV 1991 made this exemption optional for Member countries, which may restrict the breeder's rights "in order to permit farmers to use for propagating purposes, on their own holdings, the product of the harvest which they have obtained by planting on their own holdings" (Article 15 (2) ). This exemption, in addition, is to be applied "within reasonable limits and subject to the safeguarding of the legitimate interests of the breeder". Thus, the Diplomatic Conference that adopted the 1991 revision indicated that Article 15 (2) should not be interpreted as extending the "privilege" to sectors of agricultural or horticultural production where it is not "a common practice". 695 Here again, UPOV 1991 provided for a considerable strengthening of the exclusive breeders' rights. While under UPOV 1978, farmers were authorized to re-use in any way protected material without the obligation to pay any royalty to commercial breeders, 696 Article 15 (2) of UPOV 1991 results in an important limitation of the farmers' privilege. Farmers are not allowed to sell protected seeds, but are limited to their re-use for propagating purposes on their own land. 697 also intended to ensure that patent rights and breeders' rights operate in a harmonious fashion in jurisdictions where plants and their parts, seeds and genes are patentable and access to these could be blocked by patent holders. Such a practice would undermine one of the main justifications for breeders' rights protection, which is that breeders should be able to secure returns on their investments but without preventing competitors from being able freely to access breeding material. An example here might be useful. Let us consider the case of a breeders' right-protected variety called A and a patented genetic element owned by a separate company. The owner of a patent on this genetic element is free to use A to produce his or her variety B and, absent of the essential derivation provision, place B on the market with no obligations to the owner of A despite the fact that B differs from A only in the addition of the patented genetic element. However, the owner of A would need a license from the producer of B to use the patented genetic element in the breeding of further varieties. In such a situation, then, patents can have the effect of blocking the breeders' exemption that breeders' rights normally provide. It should be noted here that the breeders' right-issuing office will not itself determine whether a variety is essentially derived from an earlier one. This will be left to the courts. It is noteworthy that the EC Directive on the Legal Protection of Biotechnological Inventions seeks to make breeders' rights and patents operate more harmoniously by providing that where the acquisition or exploitation of a breeder's right is impossible without infringing a patent, or vice versa, a compulsory license may be applied for. If issued, the licensor party will be entitled to cross-license the licensee's patent or breeder's right. 695 It should be noted that the UPOV Convention contains minimum standards of protection and, hence, any member country may decide to provide higher protection than that resulting from the Convention rules. 696 See Dhar, p. 15.
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The UPOV Convention also allows access to and the use of protected material without the consent of the title-holder in cases of public interest, against an equitable remuneration.
Convention on Biological Diversity
The Convention on Biological Diversity (CBD) of 1992 deals with the conservation and sustainable use of genetic resources. It recognizes the states' sovereign rights over the genetic resources residing in their jurisdictions (Article 3). The Convention requires each Contracting Party to implement several measures in order to ensure the in-situ and ex-situ conservation of genetic resources.
Article 15 of the CBD recognizes the authority of national governments to determine access to genetic resources, subject to national legislation. 698 Notwithstanding this recognition, each Contracting Party "shall endeavour to create conditions to facilitate access to genetic resources for environmentally sound uses by other Contracting Parties and not to impose restrictions that run counter to the objectives of this Convention" (Article 15.2).
According to Article 15 para. 4 and 5 of the Convention, access, where granted, shall be on mutually agreed terms and subject to prior informed consent (PIC) of the Contracting Party providing genetic resources, 699 unless otherwise determined by that Party. In addition, the CBD stipulates that each Contracting Party shall endeavour to develop and carry out scientific research based on genetic resources provided by other Contracting Parties with the full participation of, and where possible in, such Contracting Parties. Most importantly, each Contracting Party is bound to take legislative, administrative or policy measures with the aim of sharing in a fair and equitable way the results of research and development and the benefits arising from the commercial and other utilization of genetic resources with the Contracting Party providing such resources. Such sharing shall be upon mutually agreed terms (Article 1 para. 6 and 7).
Article 16 regulates the access to and transfer of technology, which are deemed "essential elements for the attainment of the objectives" of the Convention. Contracting Parties undertake to provide and/or facilitate access for and transfer to other Contracting Parties of "technologies that are relevant to the conservation and sustainable use of biological diversity or make use of genetic resources and do not cause significant damage to the environment" (Article 16.1). For the case of developing countries, access "shall be provided and/or facilitated under fair and most favourable terms, including on concessional and preferential terms 698 Under the framework established by the 1983 International Undertaking on Plant Genetic Resources (IU, the predecessor of the 2001 International Treaty on Plant Genetic Resources for Food and Agriculture), plant genetic resources for food and agriculture (PGRFA) were deemed a "common heritage of mankind" and subject to a system of free exchange among the parties to the IU ("Plant genetic resources are a common heritage of mankind to be preserved, and to be freely available for use, for the benefit of present and future generations", IU Preamble). 699 For the purpose of the Convention, the "genetic resources being provided by a Contracting Party" are only those that are provided by Contracting Parties that are countries of origin of such resources or by the Parties that have acquired the genetic resources in accordance with the Convention (Article 15.3). Patents: biotechnological inventions where mutually agreed, and, where necessary, in accordance with the financial mechanism established by Articles 20 and 21" (Article 16.2).
The Convention addresses the case where technologies that are relevant to the conservation and sustainable use of biological diversity or make use of genetic resources are subject to intellectual property rights. In such a case, the access and transfer shall be provided on terms which recognize and are consistent with the "adequate and effective protection" of intellectual property rights (Article 16.2) . However, the Contracting Parties shall cooperate "subject to national legislation and international law in order to ensure that such rights are supportive of and do not run counter to its objectives" (Article 16.5).
Moreover, each Contracting Party undertakes to take legislative, administrative or policy measures, as appropriate, with regard to intellectual property, the handling of biotechnology and the distribution of its benefits, with the aim that r Priority access by Contracting Parties, especially developing countries, is promoted on a fair and equitable basis to the results and benefits arising from biotechnologies based upon genetic resources provided by those Contracting Parties. Such access shall be on mutually agreed terms (Article 19.2).
Finally, each Contracting Party shall, directly or by requiring any natural or legal person under its jurisdiction providing any living modified organism resulting from biotechnology, provide any available information about the use and safety regulations required by that Contracting Party in handling such organisms, as well as any available information on the potential adverse impact of the specific organisms concerned to the Contracting Party into which those organisms are to be introduced (Article 19.4).
The relationship between the provisions of TRIPS and the CBD has given rise to different opinions, 700 ranging from perfect harmony to collision. The collision has been associated with the possible granting of IPRs, based on or consisting of genetic resources, without observing the prior informed consent and benefit sharing obligations established by the CBD. It has also been held that a possible conflict may arise in the context of the implementation of both instruments, but not necessarily as a result of normative contradictions. 702 Plant and animal varieties are not patentable in the majority of countries.
703 Based on the exceptions allowed by TRIPS, some developing countries have explicitly excluded the patentability of pre-existing biological materials, including genes, unless they are genetically altered. Patents may still be granted, in these cases, for the process used to obtain a biotechnology-based product.
For most developing countries, Article 27. Peru has established a comprehensive legal system for the protection of traditional knowledge associated with biodiversity. 707 This law reflects the CBD requirements of prior informed consent and benefit sharing. It enables indigenous and local communities to assert their rights over collectively held knowledge. For this purpose, the law obliges interested parties to obtain the prior informed consent of those communities providing the biodiversity-related knowledge. In case of industrial or commercial use, interested parties are required to sign a contract with an organization representing the indigenous communities. According to Article 27 of the new law, such contracts (or licences) have to include, inter alia, the right of indigenous communities to claim a minimum compensation, i.e. 5 percent of gross sales of commercial products derived from collective knowledge. 708 This multilateral system of exchange operates by means of a standard Material Transfer Agreement to be adopted by the 706 For the purpose of clause (iv) branded seed means any seed put in a package or any other container and labeled in a manner indicating that such seed is of a variety protected under this Act. 707 As far as the relationship between the ITPGRFA and TRIPS is concerned, it is in particular Article 12.3(d) of the ITPGRFA that has been subject to controversy.
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There are several areas of possible conflict of those two agreements. Article 12.3(d) and (f ), dealing with access to plant genetic resources for food and agriculture, provides that such access shall be provided, inter alia, according to the following conditions:
(d) Recipients shall not claim any intellectual property or other rights that limit the facilitated access to the plant genetic resources for food and agriculture, or their genetic parts or components, in the form received from the Multilateral System; (emphasis added) (f ) Access to plant genetic resources for food and agriculture protected by intellectual and other property rights shall be consistent with relevant international agreements, and with relevant national laws; Paragraph (f ) makes clear that the ITPGRFA is not intended to circumvent the disciplines of TRIPS. It thus informs the interpretation of paragraph (d), which cannot be seen as an authorization of the Parties to violate the TRIPS patent provisions. According to its terms, paragraph (d) does not disallow the patenting of plant genetic resources in general, but only in the form received from the Multilateral System. This clearly excludes the patenting of seeds as acquired from a seed bank. On the other hand, it is not clear if the provision also excludes the patenting of such genetic material that has been modified or isolated from its natural environment. A more detailed analysis of this issue would however go beyond the scope of this book.
Finally, Article 13 of the ITPGRFA provides that benefits accruing from the facilitated access to the covered plant genetic resources shall be shared fairly and equitably (Article 13.1). Four benefit-sharing mechanisms are foreseen (Article 13.2): exchange of information; access to and transfer of technology; capacity building; and sharing of the benefits arising from commercialization.
Article 13.2(b)(i) of the Treaty subjects the access to and transfers of technology to the respect of applicable property rights and access laws. Subsection (d)(ii) of the same provision specifies that the standard Material Transfer Agreement (i.e. the Treaty's standardized means of providing facilitated access to the covered genetic resources) shall include a requirement obliging recipients of material accessed from the Multilateral System to pay to a specific financial resources body an equitable share of the benefits arising from the commercialization of products incorporating such material. 713 In the same context, the COP also addressed the relationship between IPRs and genetic resources and associated traditional knowledge: "7. Requests the Ad hoc Open-ended Working Group on Access and BenefitSharing to identify issues related to the disclosure of origin of genetic resources and associated traditional knowledge in applications for intellectual property rights, including those raised by a proposed international certificate of origin/source/legal provenance, and transmit the results of this examination to the World Intellectual Property Organization and other relevant forums.
8. Invites the World Intellectual Property Organization to examine, and where appropriate address, taking into account the need to ensure that this work is supportive of and does not run counter to the objectives of the Convention on Biological Diversity, issues regarding the interrelation of access to genetic resources and disclosure requirements in intellectual property rights applications, including, inter alia: (e) Intellectual property-related issues raised by proposed international certificate of origin/source/legal provenance; and regularly provide reports to the Convention on Biological Diversity on its work, in particular on actions or steps proposed to 712 On Article 15, CBD, see above, Section 5.2. Article 8( j), CBD provides that each Contracting Party shall, as far as possible and appropriate, "Subject to its national legislation, respect, preserve and maintain knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use of biological diversity and promote their wider application with the approval and involvement of the holders of such knowledge, innovations and practices and encourage the equitable sharing of the benefits arising from the utilization of such knowledge, innovations and practices". 713 address the above issues, in order for the Convention on Biological Diversity to provide additional information to the World Intellectual Property Organization for its consideration in the spirit of mutual supportiveness; 9. Invites the United Nations Conference on Trade and Development and other relevant international organisations to examine the issues in, and related to, the matters specified in paragraphs 7 and 8 in a manner supportive of the objectives of the Convention on Biological Diversity and prepare a report for submission to the on-going process of the work of the Convention on Biological Diversity on access and benefit sharing." 714 and medium farmers and breeders are likely to suffer the most devastating impact. 724 In the opinion of the proponents of an expanded and reinforced, patent-based approach, however, protection is required to provide an incentive to innovate and the necessary reward for R&D high investments. In their view, the possible negative impact of IPR protection would be offset by benefits in terms of new and better plant varieties.
The possible development of sui generis regimes for plant varieties and for traditional knowledge 725 has also attracted considerable interest as means to do justice to traditional and indigenous communities, and to provide them with economic compensation for their contributions. 726 Finally, attention shall be drawn to the recommendations adopted by the Commission on Intellectual Property Rights (IPR Commission) in its final report. As to plants and intellectual property protection, the Commission concluded:
"Developing countries should generally not provide patent protection for plants and animals, as is allowed under Article 27.3(b) of TRIPS, because of the restrictions patents may place on use of seed by farmers and researchers. Rather they should consider different forms of sui generis systems for plant varieties.
Those developing countries with limited technological capacity should restrict the application of patenting in agricultural biotechnology consistent with TRIPS, and they should adopt a restrictive definition of the term "micro-organism."
Countries that have, or wish to develop, biotechnology-related industries may wish to provide certain types of patent protection in this area. If they do so, specific exceptions to the exclusive rights, for plant breeding and research, should be established. The extent to which patent rights extend to the progeny or multiplied product of the patented invention should also be examined and a clear exception provided for farmers to reuse seeds.
The continuing review of Article 27.3(b) of TRIPS should also preserve the right of countries not to grant patents for plants and animals, including genes and genetically modified plants and animals, as well as to develop sui generis regimes for the protection of plant varieties that suit their agricultural systems. Such regimes should permit access to the protected varieties for further research and breeding, and provide at least for the right of farmers to save and plant-back seed, including the possibility of informal sale and exchange." 727 acquisitions by multinational companies in order to control or benefit from other companies' patents. This again creates important entry barriers to innovative start-ups, thus raising serious concerns about the maintenance of effective competition in the agricultural industries' sector. See IPR Commission report, p. 65. The report is available at <http://www.iprcommission.org/ graphic/documents/final report.htm>. The page numbers refer to the pdf version of the full report as available on the internet and as a hard copy. 724 
